Lipitor Pricing Offsets Loss In Prescription Volume, Pfizer Says
Declines in Lipitor's prescription volume due to the presence of generic simvastatin are being offset by price increases, Pfizer says
You may also be interested in...
The largest Medicare Part D sponsors are taking a variety of approaches to Zocor's formulary position following the introduction of a generic version of simvastatin, but they are not going to some of the extremes that non-Medicare commercial plans are
The mixed response to Merck's efforts to reach rebate agreements with health plans to place brand Zocor on the lowest cost-sharing tiers of their formularies suggests it is unlikely such a strategy would be broadly adopted by brand firms going forward
Although Lipitor has taken a beating in the run up to the launch of generics of Merck's Zocor, Pfizer is gearing up for a second round of movement in the cholesterol market, during which patients inadequately controlled on generic statins will switch to Lipitor, Pfizer CEO Hank McKinnell said June 13